CTOs on the Move

Umoja Biopharma

www.umoja-biopharma.com

 
Umoja is developing a new approach to cancer therapy that retools a patient`s immune system in vivo, enhancing the body`s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Umoja Biopharma raised $53M on 11/18/2020
Umoja Biopharma raised $210M on 06/15/2021

Similar Companies

Headway

Headway.co is a digital marketing agency that offers holistic services to help businesses scale their growth. From innovative digital strategies to custom web design and development, Headway.co specializes in conversion optimization and delivering meas...

Oncopeptides AB

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers.

Adherium

Adherium (ASX.ADR) is a global leader in digital health technologies which address sub-optimal medication use in chronic disease.

CanAm Bioresearch

CanAm Bioresearch is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellectis

Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.